Florida GLP-1 Coverage Guide
Florida has restrictive GLP-1 access for obesity, with Medicaid not covering weight-loss medications. Commercial coverage varies widely, and many patients use manufacturer programs or telehealth.
Medically reviewed by Dr. Sarah Chen, PharmD • Last updated April 2026
Medicaid Status
Medicaid coverage for GLP-1 medications is currently limited in this state.
Medicare Eligibility
Medicare Part D may cover GLP-1 medications for eligible indications.
Coverage Overview
Florida has restrictive GLP-1 medication access for obesity treatment, similar to Texas and other states that did not expand Medicaid. However, Florida’s large Medicare population (over 4.5 million enrollees — the second-highest in the nation) means the upcoming federal Medicare GLP-1 Bridge Program will have an outsized impact here. For commercially insured patients, coverage depends heavily on your specific employer plan, and many Floridians turn to manufacturer savings programs or telehealth providers for affordable access.
Florida Medicaid
Florida Medicaid covers GLP-1 medications for Type 2 diabetes management through its Statewide Medicaid Managed Care (SMMC) plans but does not currently cover anti-obesity medications for weight loss alone. All Florida Medicaid is delivered through managed care organizations:
- Aetna Better Health of Florida — covers GLP-1s for diabetes with prior authorization
- Humana Medical Plan (Medicaid) — covers semaglutide and tirzepatide for diabetes after step therapy
- Molina Healthcare of Florida — covers with PA; preferred agents vary by formulary cycle
- Sunshine Health — covers GLP-1s for Type 2 diabetes; requires documented A1C and prior therapy attempts
Medicaid eligibility in Florida is restrictive: primarily covers children, pregnant women, elderly individuals, and people with disabilities. Parents with income above approximately 28% of the Federal Poverty Level (~$6,700/year for a family of three) generally do not qualify. Florida has not expanded Medicaid under the ACA, leaving roughly 800,000 residents in the coverage gap.
For Medicaid-enrolled patients with diabetes, prior authorization requires documentation of current A1C levels, failure or intolerance of first-line diabetes medications (typically metformin), and BMI/weight records.
Commercial Insurance
Florida’s commercial insurance market offers inconsistent GLP-1 coverage:
- Florida Blue (BCBS of Florida) — the state’s largest commercial insurer covers GLP-1s for diabetes. Obesity coverage varies by employer plan selection and has been expanding in 2025–2026.
- Aetna (FL) — diabetes coverage is standard; anti-obesity medication coverage requires specific plan riders.
- UnitedHealthcare (FL) — varies by employer. Check your specific plan formulary for Wegovy, Zepbound, or other GLP-1 listings.
- Cigna (FL) — diabetes coverage standard; weight management coverage plan-dependent.
- Humana (FL) — as a major Florida-based insurer, Humana has been expanding GLP-1 coverage for weight management in select employer plans.
Prior authorization is required by nearly all Florida commercial insurers. Expect documentation requirements including BMI, comorbidity records, and evidence of lifestyle modification attempts (typically 3–6 months).
Medicare in Florida
Florida has the second-largest Medicare population in the country, making federal Medicare changes especially impactful here. Current status:
- Type 2 diabetes: GLP-1s (Ozempic, Mounjaro, Trulicity) are covered under Part D formularies with standard PA requirements.
- Weight management: The Medicare GLP-1 Bridge Program launching July 2026 will cover Wegovy and Zepbound for beneficiaries with obesity (BMI ≥30) and established cardiovascular disease. Given Florida’s large elderly population with high rates of obesity and heart disease, this program could benefit hundreds of thousands of Floridians.
- January 2027: The BALANCE Model expands Medicare coverage to additional obesity comorbidities beyond cardiovascular disease.
Contact your Part D plan directly to verify current formulary status and prepare prior authorization documentation ahead of the Bridge Program launch.
Appeals Process
Florida provides consumer protections for insurance denials:
- Internal appeal (Grievance): File within 60 days of denial. Florida-regulated plans must respond within 30 days (72 hours for urgent/expedited cases).
- External review: If internal appeal is denied, request an independent external review through the Florida Office of Insurance Regulation (OIR). For HMO plans, complaints go to the Agency for Health Care Administration (AHCA) at 1-888-419-3456.
- Documentation strategy: Include physician letter of medical necessity, BMI and weight history, comorbidity records, documentation of prior lifestyle modification, and clinical evidence supporting GLP-1 treatment (SELECT trial cardiovascular data is particularly compelling for Medicare appeals).
Telehealth and Cash-Pay Options
Florida residents have access to all major telehealth GLP-1 providers:
- Manufacturer programs: NovoCare (Wegovy Pill at $149/month, injectable Wegovy at $349/month), LillyDirect (Zepbound at $299–449/month)
- Telehealth platforms: Hims, Ro, Found, Calibrate, Noom Med — all operate in Florida
- Compounded options start at $149/month, though availability has decreased since the FDA’s February 2026 regulatory changes
Florida’s telehealth laws allow full prescriptive authority via video consultation for GLP-1 medications, and the state’s warm climate eliminates cold-chain shipping concerns that affect some northern states during winter months.